Sotatercept治疗儿童肺动脉高压:儿童肺动脉高压网络经验
结果显示WHO功能分级改善或稳定,六分钟步行距离、NT-proBNP、平均肺动脉压和肺血管阻力均显著改善,不良事件发生率为50%,出血占23%。
要点
- Sotatercept附加治疗可改善儿童肺动脉高压患者的功能分级和运动能力。
- 治疗中位323天,肺血流动力学指标显著改善,耐受性总体良好。
- 不良事件发生率50%,出血事件占23%,需关注出血风险。
核心结论
- 儿童肺动脉高压患者接受Sotatercept附加治疗可改善功能分级及其他疾病指标,且总体耐受良好。
研究设计与样本
- 多中心回顾性研究,纳入儿童肺动脉高压网络及机构登记中≤21岁的儿童和年轻成人肺动脉高压患者。
主要发现
- 40例(60%)为女性,开始Sotatercept治疗时中位年龄15.3岁(范围3.0-21.0),61例(92%)为第1组肺动脉高压。
- WHO功能分级改善者占51%,无一例恶化(p<0.0001)。
- 六分钟步行距离中位改善31米(p=0.0003,n=40),NT-proBNP中位下降378 pg/ml(p<0.0001,n=26)。
- 平均肺动脉压中位下降17 mmHg(p<0.0001,n=21),肺血管阻力中位下降4.4 WUi(p=0.0011,n=21)。
- 38例中有13例停用或减量肠外前列环素;不良事件发生于33例(50%),出血15例(23%);无患者升级肺动脉高压治疗、因临床恶化住院、接受肺移植或死亡。
临床怎么用
- 对于儿童肺动脉高压患者,Sotatercept可作为附加治疗选择,需监测出血等不良事件。
局限性
- 回顾性研究设计,样本量有限,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sotatercept, a ligand trap for TGF-β family members, has been shown to improve exercise capacity and decrease pulmonary vascular resistance (PVR) in adults with pulmonary arterial hypertension. Limited data exist describing the use of sotatercept in children with pulmonary hypertension (PH). RESEARCH QUESTION: What is the safety and efficacy of sotatercept as add-on therapy in children with PH. STUDY DESIGN AND METHODS: This is a multi-center, retrospective study of children and young adults ≤ 21 years of age with pediatric PH treated by programs in the Pediatric PH Network and institutional registries. Demographic data and clinical characteristics before and after sotatercept initiation were collected. RESULTS: Sixty-six subjects received sotatercept as add-on therapy for a median duration of 323 days (Interquartile range 239, 500). Forty (60%) were female with median age 15.3 years (range 3.0 - 21.0) at initiation of sotatercept, and 61 with Group 1 (92%) PH. WHO functional class improved in 51% and did not worsen in any subjects (p < 0.0001). Subjects experienced significant improvement in six-minute walk distance (median 31 m, p=0.0003, n=40), NT-proBNP (median decrease 378 pg/ml, p< 0.0001, n=26), mean pulmonary artery pressure (median decrease 17 mmHg, p<0.0001, n=21), and PVR (median decrease 4.4 WUi, p=0.0011, n=21). Parenteral prostacyclin was weaned or discontinued in 13 of 38 patients. Adverse events occurred in 33 (50%) subjects with bleeding in 15 (23%). No patients had escalation of PH therapy, were hospitalized for clinical worsening, underwent lung transplant, or died. INTERPRETATION: Pediatric PH patients treated with sotatercept as add-on therapy demonstrated improvement in functional class and other PH disease indicators and was generally well tolerated.
引用
- Critser PJ, Krishnan US, Avitabile CM, et al. Sotatercept in Pediatric Pulmonary Hypertension: Experience from the Pediatric Pulmonary Hypertension Network. Chest. 2026. PMID: 42833549. doi:10.1016/j.chest.2026.09.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。